Abstract:Abstract Purpose: Current systems of gastric cancer (GC) molecular classification include genomic, molecular, and morphological features. GC classification based on tissue metabolomics remains lacking. This study aimed to define metabolically distinct GC subtypes and identify their clinicopathological and molecular characteristics. Experimental Design: Spatial metabolomics by high mass resolution imaging mass spectrometry was performed in 362 GC patients. K−means clustering was used to define tumor and stroma-related subtypes based on tissue metabolites. The identified subtypes were linked with clinicopathological characteristics, molecular features, and metabolic signatures. Responses to trastuzumab treatment were investigated across the subtypes by introducing an independent patient cohort with HER2-positive GC from a multicenter observational study. Results: Three tumor- and three stroma-specific subtypes with distinct tissue metabolite patterns were identified. Tumor-specific subtype T1(HER2+MIB+CD3+) positively correlated with HER2, MIB1, DEFA-1, CD3, CD8, FOXP3, but negatively correlated with MMR. Tumor-specific subtype T2(HER2−MIB−CD3−) negatively correlated with HER2, MIB1, CD3, FOXP3, but positively correlated with MMR. Tumor-specific subtype T3(pEGFR+) positively correlated with pEGFR. Patients with tumor subtype T1(HER2+MIB+CD3+) had elevated nucleotide levels, enhanced DNA metabolism, and a better prognosis than T2(HER2−MIB−CD3−) and T3(pEGFR+). An independent validation cohort confirmed that the T1 subtype benefited from trastuzumab therapy. Stroma-specific subtypes had no association with clinicopathological characteristics, however linked to distinct metabolic pathways and molecular features. Conclusions: Patient subtypes derived by tissue-based spatial metabolomics are a valuable addition to existing GC molecular classification systems. Metabolic differences between the subtypes and their associations with molecular features could provide a valuable tool to aid in selecting specific treatment approaches.

Supplementary Data from Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients

Spatial metabolomics identifies distinct tumor-specific subtypes in gastric cancer patients

A Proteomic Landscape of Diffuse-Type Gastric Cancer

Metabolic Signature-Based Subtypes May Pave Novel Ways for Low-Grade Glioma Prognosis and Therapy.

Supplementary Dataset 1 from Distinct Subtypes of Gastric Cancer Defined by Molecular Characterization Include Novel Mutational Signatures with Prognostic Capability

The Combination of Exon Sequencing and Metabolomics to Establish a Molecular Typing System for Gastric Cancer

Supplementary Dataset 3 from Distinct Subtypes of Gastric Cancer Defined by Molecular Characterization Include Novel Mutational Signatures with Prognostic Capability

Supplementary Dataset 2 from Distinct Subtypes of Gastric Cancer Defined by Molecular Characterization Include Novel Mutational Signatures with Prognostic Capability

Spatially resolved multi-omics highlights cell-specific metabolic remodeling and interactions in gastric cancer

Supplementary Table 1 from Distinct Subtypes of Gastric Cancer Defined by Molecular Characterization Include Novel Mutational Signatures with Prognostic Capability

Molecular Characterization and Clinical Relevance of Metabolic Signature Subtypes in Gastric Cancer

Dissecting gastric cancer heterogeneity and exploring therapeutic strategies using bulk and single-cell transcriptomic analysis and experimental validation of tumor microenvironment and metabolic interplay

Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD.

Single-cell landscape reveals active cell subtypes and their interaction in the tumor microenvironment of gastric cancer

Supplementary Figure 1 from Distinct Subtypes of Gastric Cancer Defined by Molecular Characterization Include Novel Mutational Signatures with Prognostic Capability

Characterization of Glycometabolism and Tumor Immune Microenvironment for Predicting Clinical Outcomes in Gastric Cancer.

Supplementary Data from A Wnt-Independent LGR4–EGFR Signaling Axis in Cancer Metastasis

Data Supplement from Large-Scale Characterization of DNA Methylation Changes in Human Gastric Carcinomas with and without Metastasis

Unraveling metabolic characteristics and clinical implications in gastric cancer through single-cell resolution analysis

Supplementary Data from Spatial Organization and Prognostic Significance of NK and NKT-like Cells Via Multimarker Analysis of the Colorectal Cancer Microenvironment

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes